Anaplastic large-cell lymphoma (ALCL) is a type of peripheral T-cell lymphoma; currently, only one immunotherapeutic agent is approved for the treatment of this disease.
Approved immunotherapeutic agents
Combination therapy/treatment algorithms
Approved immunotherapeutic agents (for anaplastic large-cell lymphoma)
The anti-CD30 antibody-drug conjugate brentuximab vedotin was approved in 2011 for the treatment of ALCL in patients who have not responded to systemic chemotherapy.
Anaplastic large-cell lymphoma combination therapy/treatment algorithms
Brentuximab vedotin is recommended as second-line therapy in patients with CD30-positive ALCL who have progressed after systemic chemotherapy. Currently, is it recommended only as a single agent and not in combination with any other treatment.
Current clinical trials for anaplastic large-cell lymphoma
Pembrolizumab is currently being investigated in a phase 2 trial for the treatment of relapsed or refractory ALCL, and the investigative agent MEDI-570, an anti–inducible T-cell costimulator (a cell surface marker expressed on T cells) monoclonal antibody, is in phase 1 testing.